Core Insights - Surrozen is advancing targeted protein degradation (TPD) technologies to enhance Wnt-signal activation for treating liver diseases, specifically through the development of ASGR-targeted bispecific antibodies [1][7][10] - The company has initiated a Phase 1b clinical trial for SZN-043, focusing on severe alcohol-associated hepatitis, with proof-of-concept data expected in the first half of 2025 [3][9] Group 1: TPD Technologies and Research - The publication highlights the development of two new ASGR-targeted SWEETS bispecific antibodies that activate Wnt signaling through a unique TPD platform, enhancing liver function in mouse models [1][8] - A review article published in iScience summarizes the progress in Wnt activating platforms, emphasizing the potential of Wnt agonists in treating tissue degenerative diseases [2] Group 2: Clinical Development - SZN-043 is the first candidate utilizing Surrozen's SWEETS technology, having completed a Phase 1a clinical trial demonstrating safety and target engagement [3][9] - The Phase 1b clinical trial for SZN-043 began enrollment in Q2 2024, with expectations for proof-of-concept data in early 2025 [9] Group 3: Company Overview - Surrozen is a clinical-stage biotechnology company focused on discovering and developing drug candidates that selectively modulate the Wnt pathway, targeting severe liver and eye diseases [5][10] - The company's proprietary technologies aim to overcome limitations in pursuing the Wnt pathway as a therapeutic strategy, with a focus on tissue-specific antibodies [10]

Core Insights - Surrozen, Inc. is advancing its clinical development of SZN-043, a novel biotherapeutic aimed at enhancing Wnt signaling for liver regeneration, particularly in severe alcohol-associated hepatitis [6][11] - The Phase 1a trial of SZN-043 demonstrated safety and tolerability in both healthy volunteers and patients with liver cirrhosis, with evidence of target engagement and pharmacodynamic effects [5][7][11] - Enrollment for the Phase 1b trial in severe alcohol-associated hepatitis began in Q2 2024, with proof-of-concept data expected in early 2025 [6][13] Company Overview - Surrozen is a clinical-stage biotechnology company focused on developing targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration [16] - The company is also developing SZN-413, a bi-specific antibody for retinal diseases, in partnership with Boehringer Ingelheim, which includes an upfront payment of $12.5 million and potential milestone payments totaling up to $587 million [8][16] Clinical Trial Results - The Phase 1a trial involved 40 healthy volunteers and 8 patients with liver cirrhosis, with intravenous doses ranging from 0.5 mg/kg to 3 mg/kg [6][11] - Results indicated transient increases in alkaline phosphatase (ALP) and activation of Wnt signaling, as evidenced by improved liver function metrics [2][5][12] Future Developments - Surrozen is focused on optimizing its platform technologies to enhance Wnt pathway modulation, which is seen as a promising mechanism for liver regeneration [7][15] - The company aims to leverage its proprietary SWEETS™ technology for the development of SZN-043 and other therapeutics targeting severe liver diseases [7][11]

About Surrozen Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis Enrollment is ongoing in Phase 1b study in severe alcohol-associated hepatitis Study Overview Pharmacodynamic Biomarkers The study provided evidence of Wnt-mediated pharmacodynamic activity in the liver after treatment with SZN043. "We were pleased to present the first clinical data from this innovative bispecific antibody-based approach to modulating t ...

SOUTH SAN FRANSCISO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical trial for SZN-043 in patients with severe alcohol-associated hepatitis. In the fourth quarter of 2022, Surrozen entered into a strategic partnership with Boehringer Ingelheim for the resea ...

SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1 Anticipate potential proof-of-concept data available in the first half of 2025 SOUTH SAN FRANSCISO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that the first patient has been dosed in its Phase 1b clinical trial for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 30-1374889 | | --- | --- | | ( State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 171 Oyster Point Blvd, Suite 400, Sout ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39635 Surrozen, Inc. (Exact name of registrant as specified in its charter) | Delaware 30-1374889 | | --- | | (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 30-1374889 | | --- | --- | | ( State ...

WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 98-1556622 | | --- | --- | | ( State or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39635 Surrozen, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 98-1556622 | | --- | --- | | ( State or ...